These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 20357763)

  • 21. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET.
    Tinianow JN; Gill HS; Ogasawara A; Flores JE; Vanderbilt AN; Luis E; Vandlen R; Darwish M; Junutula JR; Williams SP; Marik J
    Nucl Med Biol; 2010 Apr; 37(3):289-97. PubMed ID: 20346868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
    Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
    J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-Human Evaluation of Site-Specifically Labeled
    Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
    J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 89Zr-bevacizumab PET imaging in primary breast cancer.
    Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
    J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
    Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    Eisses B; van Geel JJL; Brouwers AH; Bensch F; Elias SG; Kuip EJM; Jager A; van der Vegt B; Lub-de Hooge MN; Emmering J; Arens AIJ; Zwezerijnen GJC; Vugts DJ; Menke-van der Houven van Oordt CW; de Vries EGE; Schröder CP
    J Nucl Med; 2024 Oct; 65(10):1540-1547. PubMed ID: 39237347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for
    O'Donoghue JA; Lewis JS; Pandit-Taskar N; Fleming SE; Schöder H; Larson SM; Beylergil V; Ruan S; Lyashchenko SK; Zanzonico PB; Weber WA; Carrasquillo JA; Janjigian YY
    J Nucl Med; 2018 Jan; 59(1):161-166. PubMed ID: 28637800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
    England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
    Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted
    Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS
    Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours.
    Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B
    Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
    J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
    MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Jauw YWS; O'Donoghue JA; Zijlstra JM; Hoekstra OS; Menke-van der Houven van Oordt CW; Morschhauser F; Carrasquillo JA; Zweegman S; Pandit-Taskar N; Lammertsma AA; van Dongen GAMS; Boellaard R; Weber WA; Huisman MC
    J Nucl Med; 2019 Dec; 60(12):1825-1832. PubMed ID: 31147401
    [No Abstract]   [Full Text] [Related]  

  • 39. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
    Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
    J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
    den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
    J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.